A Novel Compound <scp>QO</scp>‐83 Alleviates Acute and Chronic Epileptic Seizures in Rodents by Modulating <scp>KV7</scp> Channel Activity

Xiangyu Wang, Yang Zhang, Hui Liu, Jiahao Wang, Boxuan Zhang, Tenghui He, Huiran Zhang, Zhuang Xiong, Xingang Liu, Jincan Li, Weidong Zhao, Xiao Liu, Wei Zhang, Le Yang, Qian Li, Hailin Zhang, Jinlong Qi, Qingzhong JiaCNS 2025 · DOI

TL;DR

Researchers have developed a new drug candidate, QO-83, that shows promise in treating epilepsy by targeting Kv7 channels. Unlike existing treatments that have significant side effects, QO-83 demonstrates superior efficacy, stability, and a better safety profile in preclinical rodent models, suggesting it could be a valuable new antiepileptic therapy.

What Problem Does This Paper Address?

Epilepsy affects millions worldwide and is characterized by abnormal neuronal firing. Kv7 channels are a key target for antiepileptic drugs because they help stabilize neuronal membranes and reduce excitability. However, the most well-known Kv7 channel opener, retigabine (RTG), was withdrawn from the market due to severe side effects like blue discoloration of tissues and urinary retention. Furthermore, RTG has poor brain penetration, requiring higher doses and increasing the risk of off-target effects. This creates a critical need for new Kv7 channel openers with improved efficacy, stability, and safety profiles.

Methods

The study employed a multi-faceted approach to evaluate QO-83:

  • Electrophysiology: Patch-clamp techniques were used to measure Kv7 channel activity in vitro, assessing QO-83's potency and selectivity for different Kv7 channel subtypes. They also examined its effects on neuronal excitability (action potential firing, resting membrane potential) and synaptic currents (sEPSCs and sIPSCs) in brain slices.
  • In Vivo Epilepsy Models: QO-83 was tested in various established rodent models of epilepsy, including:
  • Pilocarpine-induced status epilepticus (SE)

    • Maximal Electroshock Seizure (MES) model
    • Metrazol Maximal Seizure (MMS) model
    • Penicillin (PNC)-induced acute epilepsy model
    • Chronic PTZ-induced epileptic kindling model EEG recordings were used in some models to assess brain activity.
  • Molecular Dynamics Simulations: These simulations were used to investigate the binding mechanism of QO-83 and RTG to the Kv7.2 channel at an atomic level, comparing their stability and interactions.

  • Pharmacokinetic Assessment: The brain-to-plasma drug concentration ratio was measured to assess blood-brain barrier penetration.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from in vitro assays and in vivo animal models.

Key Insights and Ideas

  • Targeted Selectivity: QO-83 shows a strong preference for opening Kv7.2 and Kv7.2/7.3 channels, which are highly expressed in the brain and crucial for neuronal excitability. This selectivity is a key advantage over RTG, which has broader effects.
  • Enhanced Efficacy: QO-83 demonstrates superior efficacy in activating Kv7.2 channels compared to RTG, shifting the voltage dependence of activation more significantly and promoting channel opening more effectively.
  • Improved Stability and Safety: QO-83 exhibits excellent chemical stability and a significantly better brain-to-plasma ratio than RTG, suggesting improved pharmacokinetic properties and reduced systemic exposure for equivalent therapeutic effects. Crucially, it did not induce the characteristic blue discoloration seen with RTG and showed no signs of hepatotoxicity in preclinical tests.
  • Mechanism of Action: QO-83 appears to exert its anticonvulsant effects primarily by activating Kv7 channels, leading to membrane stabilization and reduced neuronal excitability. Its effects on synaptic currents (sIPSCs and sEPSCs) further support its role in modulating neuronal communication.
  • Synergistic Inhibition: The combination of QO-83 with XE991 (a Kv7 channel blocker) suggests that XE991 can indeed antagonize QO-83's effects, reinforcing the idea that QO-83's primary mechanism involves Kv7 channel activation.

Key Results

  • In Vitro: QO-83 showed high potency (EC50=0.08±0.04µM) and selectivity for Kv7.2/7.3 channels. It shifted the voltage-dependent activation of Kv7.2-Kv7.5 channels to more hyperpolarized potentials, indicating enhanced channel opening. At 10µM, QO-83 shifted the activation V1/2 of Kv7.2 channels by -26.48mV, a greater shift than RTG.
  • Neuronal Excitability: QO-83 significantly inhibited action potential firing in mPFC and hippocampal neurons at lower concentrations (1µM) compared to RTG. It also modulated resting membrane potential and afterhyperpolarization.
  • Synaptic Currents: QO-83 significantly inhibited sEPSC amplitude without affecting frequency, and reversed the effect of Mg2+-free conditions on sIPSC amplitude.
  • In Vivo: In pilocarpine-induced SE, QO-83 (1mg/kg) significantly prolonged seizure latency and reduced seizure grade, outperforming RTG at equivalent doses. In MES and MMS models, QO-83 demonstrated dose-dependent anticonvulsant effects at significantly lower doses than RTG. For example, the ED50 for QO-83 in the MES model was 2.27±1.29mg/kg, while RTG required 15mg/kg for comparable protection. QO-83 also showed potent effects in PNC-induced and chronic PTZ kindling models.
  • Molecular Dynamics: Simulations revealed that the QO-83-Kv7.2 complex was more stable than the RTG-Kv7.2 complex, with QO-83 exhibiting a higher binding affinity (-52.95 kcal/mol) compared to RTG (-45.51 kcal/mol). W236 was identified as a key binding residue for both compounds.
  • Pharmacokinetics: QO-83 demonstrated a brain-to-plasma drug concentration ratio of 343.67%, indicating excellent blood-brain barrier penetration.

Limitations and Future Work

  • Preclinical Stage: The study is preclinical, and all results are from rodent models. Further studies are needed to confirm these findings in humans.
  • Long-Term Effects: While QO-83 showed good chemical stability, long-term in vivo stability and potential chronic side effects (beyond those observed in the study) would require further investigation.
  • Specific Subtype Interactions: While QO-83 shows selectivity for Kv7.2/7.3, a deeper understanding of its interactions with other Kv7 subtypes and potential off-target effects could be beneficial.
  • Further Development: The authors recommend further development of QO-83 and other Kv7 channel openers, suggesting that QO-83 is a promising candidate for future antiepileptic drug development.

Summary updated

Abstract

QO-83, as a newly developed Kv7.2 opener, has the advantages of stable properties, strong affinity, and high activity compared with retigabine, and is expected to become a new antiepileptic drug.
BibTeX
@inproceedings{wang2025novel,
  author = {Xiangyu Wang and Yang Zhang and Hui Liu and Jiahao Wang and Boxuan Zhang and Tenghui He and Huiran Zhang and Zhuang Xiong and Xingang Liu and Jincan Li and Weidong Zhao and Xiao Liu and Wei Zhang and Le Yang and Qian Li and Hailin Zhang and Jinlong Qi and Qingzhong Jia and Jinlong Qi and Qingzhong Jia},
  title = {{A Novel Compound <scp>QO</scp>‐83 Alleviates Acute and Chronic Epileptic Seizures in Rodents by Modulating <scp>K<sub>V</sub>7</scp> Channel Activity}},
  booktitle = {CNS},
  year = {2025},
  doi = {10.1111/cns.70334},
}
Figure